Blood pressure (BP) screening is important to identify those at risk of cardiovascular disease, but there has been little data on the appropriate interval of screening. We aimed to evaluate the optimal interval and the best measure for BP re-screening by estimating the long-term, true change variance ('signal') and shortterm, within-person variance ('noise'). Study design was a cohort study from 2005 to 2008. Target population was Japanese healthy adults not taking antihypertensive medication at baseline, in a teaching hospital. We measured annually the systolic BP (SBP) and the diastolic BP (DBP), and calculated the pulse pressure (PP) and the mean arterial pressure (MAP). A total of 15 055 individuals (51% male) with a mean age of 49 years had annual check-ups. Short-term coefficient of variation was lowest for MAP at 5.2%, followed by SBP (5.7%) and DBP (5.8%), and highest for PP (12%). After 3 years, the 'signal' of true BP changes of only SBP and MAP equaled the 'noise' of BP measurement; however, it was larger for those with higher initial BPs. SBP or MAP appears to be a better screening measure. The optimal interval should be 3 years or more, with SBPo130 mm Hg and 2 years for those with SBPX130 mm Hg.
Introduction
Hypertension is quite common in industrialized countries, [1] [2] [3] including Japan, 4 and is an important risk factor for cardiovascular disease (CVD), renal disease and eye disorders. [5] [6] [7] Large randomized controlled studies and a meta-analyses have established that antihypertensive medications reduce CVD morbidity and mortality. 8, 9 Thus, regular blood pressure (BP) screening of adults is important to identify those at risk of CVD, but there has been little data and analysis on the appropriate interval of screening.
Screening for hypertension entails the interpretation of initial BP levels and that of a series of BP levels over time, 10 in which we should consider both within-individual short-term variation and longterm variation in a population. 11 Many hypertension guidelines for primary prevention of CVD set a target level of BP for treatment and discuss how to interpret initial measurements; however, these guidelines rarely specify subsequent monitoring intervals and the guidelines vary in their recommendation.
For example, European Society of Hypertension and the European Society of Cardiology (ESH/ESC) Hypertension Guidelines suggest that patients at low risk or with grade I hypertension (systolic BP (SBP) 140-159 mm Hg/diastolic BP (DBP) 90-99 mm Hg) may be seen every 6 months. 12 The United States Preventive Services Task Force recommends screening for hypertension in adults aged 18 years and older, 13 and the optimal screening interval, however, is not clearly stated because of the lack of evidence. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 6 recommends screening every 2 years for adults aged 18 years and older, with BP o120/80 mm Hg, and every year for those with SBP of 120-139 mm Hg or DBP of 80-90 mm Hg. Moreover, the British Hypertension Society Guideline 14 in the UK recommends that people aged 40-74 years old, without a history of CVD, should have BP measured for assessment of CVD risks; those with a BP o140/90 mm Hg should be re-tested within 5 years, and those not taking antihypertensive medication with a BP X140/90 should be re-tested within 1 year. Even when guidelines suggest screening intervals, the basis for suggestions is not provided and no guidelines ever take into consideration short-term and long-term variations in the re-screening strategies.
Screening for the detection of hypertension and early intervention can reduce the morbidity and mortality of CVDs, but it also has some drawbacks, including the inconvenience and cost. In addition, false-positive results can lead to wasteful intervention. 10, 15 To minimize that risks, a good monitoring test should be able to distinguish true changes in the condition (signal) from the background variability (noise). 11, [16] [17] [18] Thus, in choosing a test, the signalto-noise (S/N) ratio is now considered as one of key index in determining the value of the monitoring test. 11 We therefore aimed to estimate the S/N ratio in BP re-screening based on two kinds of variances withdrawn from sequential BP measurements in a large cohort study. As previous studies have reported that pulse pressure (PP) and mean arterial pressure (MAP) are associated with CVD, 7, 19, 20 we compared the S/N ratio among different types of BP measures, including SBP, DBP, PP and MAP to explore an appropriate measure for monitoring.
Methods

Study participants
Between January and December 2005, we consecutively enrolled all people in an annual health checkup program at the Center for Preventive Medicine, St Luke's International Hospital in Tokyo, Japan. The purpose of this program is to promote public health through early detection of chronic diseases and their risk factors. In Japan, the Industrial Safety and Health Law obliges all workers and their families to undergo an annual health check-up at their workplace. Around 80% of all participants at the center were employees of various companies and local governmental organizations, and their families. These companies and organizations had a contract with the center and the cost for an annual check-up is largely paid for by employers. In contrast, the rest of the participants, comprising fewer than 20% of all participants at the center, independently registered for the annual check-up program. The majority of these individuals was citizens of Tokyo and paid for the check-up by themselves. As most of the participants in this program had been actually undergoing annual check-ups, we were able to formulate follow-up dataset for this large healthy adult population.
Data collection
We collected data on adults (420 years old) who had undergone annual health check-ups from 2005 to0 2008 at the Center for Preventive Medicine, St Luke's International Hospital in Tokyo, Japan. We excluded people who took antihypertensive medications at baseline. Two investigators independently extracted and recorded information using a structured data form. A consensus was reached after discussion for any points of disagreement. St Luke's International Hospital Ethics Committee Institutional Review Board approved all aspects of this study. To preserve patient confidentiality, direct patient identifiers were not collected as part of the dataset.
Measurements
Annual check-up consisted of demographic information, medical history, initial evaluation (vital sign and laboratory data) and current treatments.
Casual-screening BPs in a sitting position were measured by trained nurses; BP measurements were made twice, once after sitting quietly for several minutes and then again after at least 2 min. 12 The average of the two readings was recorded as the participant's BP. 21 A fully automatic calibrated oscillometric BP measuring device (BP-203 RV II, Colin, Japan) was used with a standard arm cuff, given that the average arm circumference for participants was less than 34 cm. 22 SBP and DBP were recorded and PP (SBPÀDBP) and MAP (1/3 SBP þ 2/3 DBP) were calculated later.
Long-term true change variance and short-term, withinperson variance
We used the direct method to estimate variance in long-term, true changes among participants and short-term, within-person variance. 23, 24 We calculated the variance of differences between the baseline value in 2005 and in each subsequent year. According to the 'variogram' method, we used a linear extrapolation backward from the longer-term measurements and estimated what the apparent variance would be at baseline. 16 By subtracting this variance at baseline (equal to twice the shortterm, within-person variance) from the variance of change, we estimated true, long-term changes among participants.
Censored values
Some participants subsequently started taking antihypertensive medication during follow-up period. To avoid including the changes caused by hypertension treatment while minimizing selection bias, we 'censored' such data and replaced subsequent values with those immediately previous for each following measurement ('last observation carried forward').
Detecting the ratio of signal (long-term variance) to noise (within-person variance) and the ratio of false positive to true positive We used the S/N ratio to estimate the optimal interval and determine the best measure for re-screening BP. 16 . A true increase of a participant's BP level consists of the average change of the whole group over time (signal) and the short-term within-person variance around the average change (noise). We aimed to identify individuals that drifted from the average population over subsequent monitoring years. This would be reflected as an increase in the long-term variance of the overall population. Therefore, the long-term variance is also part of the signal. To be a good monitoring test, the signal needs to be large relative to noise; thus, we calculated the S/N ratio by dividing signal by noise and when the S/N ratio was X1, we considered the screening interval appropriate.
Finally, based on the calculated change in variance at each time, we conducted a Monte Carlo simulation (n ¼ 1000) to estimate proportion of participants whose true baseline SBP (either 120 or 130 mm Hg) could increase beyond a threshold of 140 mm Hg. We estimate both 'true positive' (those truly increasing beyond 140 mm Hg) and the 'false positive' proportion of those whose BP would be judged to be above 140 mm Hg thresholds. From these, we calculated the ratio of false positive to true positive. We assumed that the baseline value and the true change with time are normally distributed and are independent of each other.
Statistical methods
All analyses were conducted using SPSS 15.0J. statistical software (SPSS Japan, Tokyo, Japan). Responses were analyzed using descriptive statistics, including mean, variance, s.d. and percents. A coefficient of variation was calculated by dividing s.d. by mean BP at baseline. The 95% confidence intervals were calculated using normal approximation methods. We found an increase in SBP and DBP of 1.4 mm Hg and 0.8 mm Hg, respectively, in 3 years. The trends of mean SBP and DBP slightly increased over 3 years (0.4% per year). The proportions of patients with hypertension above the threshold of 140/90 for each year were 9.2, 9.9, 10.4 and 11.9% for SBP, and 7.1, 7.7, 8.2 and 9.2% for DBP. The demographic characteristics of the participants and nonparticipants were similar (Table 1) . Figure 1 shows the direct estimates of the variance of change in each of the four BP measurements over 3 years. Based on a backward extrapolation of this 'variogram', we estimated that the variances of differences among individual BP levels at baseline were 89. Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval; HDL, high-density protein; LDL, low-density protein.
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Variation in long-term, true change
The steady average BPs may mask larger individual changes in both directions. To estimate the degrees of these individual changes, we calculated the increase in variance of differences for all BP measurements over time (Figure 1 ). Subtracting the short-term variances at baseline from the overall variance, we calculated the long-term variance, which increased from baseline to 43.6 (s. The signal-to-noise ratio The S/N ratio of SBP or MAP over 3 years was 1.0. and was better than that for other BP measures (DBP, 0.8; PP, 0.4; Table 2 ). When values were divided into three groups on the basis of baseline SBP level (o130, 130-139 and X140 mm Hg), the variance of differences also increased over time (Figure 2 ). The S/N ratio among those with a baseline SBP X130 mm Hg tended to be higher than that ratio among those with a baseline SBP o130 mm Hg (Table 3) . At year 3, the S/N ratio of SBP among those with a baseline SBP o130 mm Hg was less than 1. Among those with a baseline SBP X130 mm Hg, the S/N ratios of SBP were 1.1 and 1.6 at year 2 and 3, respectively ( Table 3) .
Probability of observed increases in blood pressured during 3-year follow-up Table 3 gives the estimated proportions of true-and false-positive measurement of SBP over threshold of 140 mm Hg from the baseline 'true' measurement of 120 or 130 mm Hg, and the ratio of false positive to true positive tests. For example, a patient with a true BP of 130 mm Hg at baseline has a 0.2% probability of truly reaching 140 mm Hg or above, 1 year later. However, the false-positive probability, true-positive probability and the ratio were 6.4, 0.1 and 64.0%, respectively, meaning that for every one true positive result, 64 other individuals would also be judged as 'false' positive due to measurement error.
Discussion
Summary of findings
This large cohort survey of adults not taking antihypertensive drugs suggests that SBP or MAP appears to be a better routine screening measure than DBP and PP, and the optimal BP measurement interval should be 3 years or more for healthy adults with SBP o130 mm Hg and 2 years for those with SBP X130 mm Hg. 
Abbreviations: CV, coefficient of variation; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; SBP, systolic blood pressure. Blood 25 and other Canadian surveys around 0.5 mm Hg per year. 26 The estimated short-term, within-person variation of 45 mm Hg 2 for SBP is comparable to the value in a previous study, 21 although the methodology used to estimate the within-person variance was different. Klungel et al. 27 found that the within-person variance of the average SBPs taken 1 year apart was 40.0 mm Hg 2 for adults aged 20-59 years (n ¼ 834). They also reported that the within-person variance increased with longer measurement intervals and fewer measurements per visit, and was influenced by the type of measurement device. 27 Cook et al. 28 showed that for the measurement interval of 3 years, the within-person variance of SBP was 71.4 mm Hg 2 , whereas for three measurements per visit, two visits 1 week apart, it decreased to 24.2 mm Hg (n ¼ 326). 29 We found that SBP and MAP are more reliable measures than DBP and PP, partly because any random measurement errors that affect SBP or DBP are halved in calculating the average. 30 Although previous studies have suggested that MAP has a greater initial independent predictive value as an initial measurement for CVD, 7, 20, 31, 32 with PP being much less informative, 30 current guidelines for primary prevention of CVD do not specifically recommend the use of MAP for re-screening. On the other hand, meta-analysis showed that for a single measurement of BP, SBP is slightly more informative than DBP for predicting CVD. 30 Thus, either SBP or MAP should be used for both evaluating initial risk and ongoing monitoring assessments.
In addition to BP levels, the variability in SBP has been reported as an independent factor in the prediction of risk of vascular events. 33, 34 In our study, the long-term variance was larger for those with higher initial SBPs, suggesting that one may predict the other. However, further research is needed in future to clarify this relationship and their relationship to short-term variability.
For the overall risk assessments of CVD, risk factors including dyslipidemia and diabetes should be taken into consideration. However, in this study, we have focused on the increase in variability of BP measurements over time and its impact on the assessment of BP, screening the interval in healthy adults. For sensitivity analysis, we stratified our participants by some risk factors based on ESH/ESC guidelines, 12 including dyslipidemia (low-density lipoprotein-cholesterol 4115 mg dl À1 (3 mmol l À1 )), diabetes (Fasting plasma glucoseX126 mg dl À1 (7.0 mmol l À1 )), age (465 years old), smoking and overweight (body mass index X25 kg m À2 ). These risk factors except overweight did not alter the signal-noise ratios of SBP measurements. Overweight, however, did not change the interval of SBP measurements. Further study is necessary regarding how other risk factors might influence re-screening in the clinical setting, for example, how best to achieve the integration of CVD risk prediction scores, such as Framingham risk score.
Limitations
Our study has some limitations. First, we collected data from only one institution in Tokyo, Japan. Although the sample size is large, findings might not be generalizable to other populations. Second, there may be some underestimation of changes of variance because of the need to impute future values in patients who began taking antihypertensive therapy. However, we believe this effect does not make a large difference to our conclusion, because only a small portion of the measurements was affected (4.8%). Third, although we used the direct method to estimate the within-person variance, it may be helpful to analyze the data using other models, such as the linear mixed model. However, we believe that the direct method provides more accurate estimates of long-term variance, because it is more conservative regarding the likelihood of 
Conclusion
Our findings support that SBP or MAP appears to be better long-term monitoring measures than DBP and PP. The optimal measurement interval should be at least 3 years for healthy adults not taking antihypertensive medications; however, the ratio were better for those with higher initial BPs. The optimal BP measurement interval should be 3 years or more for healthy adults with SBP o130 mm Hg and 2 years for those with SBP X130 mm Hg.
